RU2004103869A - Карбоциклические гидразины в качестве ингибиторов медьсодержащх аминоксидаз - Google Patents
Карбоциклические гидразины в качестве ингибиторов медьсодержащх аминоксидаз Download PDFInfo
- Publication number
- RU2004103869A RU2004103869A RU2004103869/04A RU2004103869A RU2004103869A RU 2004103869 A RU2004103869 A RU 2004103869A RU 2004103869/04 A RU2004103869/04 A RU 2004103869/04A RU 2004103869 A RU2004103869 A RU 2004103869A RU 2004103869 A RU2004103869 A RU 2004103869A
- Authority
- RU
- Russia
- Prior art keywords
- hydrogen
- optionally substituted
- formula
- compound
- alkyl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 claims abstract 35
- 201000010099 disease Diseases 0.000 claims abstract 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 9
- 150000003839 salts Chemical class 0.000 claims abstract 7
- 239000012453 solvate Substances 0.000 claims abstract 7
- 210000001789 adipocyte Anatomy 0.000 claims abstract 3
- 230000004069 differentiation Effects 0.000 claims abstract 3
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims abstract 3
- 208000019553 vascular disease Diseases 0.000 claims abstract 3
- 230000023852 carbohydrate metabolic process Effects 0.000 claims abstract 2
- 235000021256 carbohydrate metabolism Nutrition 0.000 claims abstract 2
- 230000002792 vascular Effects 0.000 claims abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 29
- 239000001257 hydrogen Substances 0.000 claims 29
- 238000000034 method Methods 0.000 claims 27
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 18
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 16
- 208000027866 inflammatory disease Diseases 0.000 claims 15
- 125000003710 aryl alkyl group Chemical group 0.000 claims 12
- 150000002431 hydrogen Chemical class 0.000 claims 11
- 125000001589 carboacyl group Chemical group 0.000 claims 6
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 5
- -1 maleate (1R, 2R) -2- (1-methylhydrazino) -1-indanol Chemical compound 0.000 claims 5
- 201000001320 Atherosclerosis Diseases 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 3
- 125000003435 aroyl group Chemical group 0.000 claims 3
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 3
- 210000002808 connective tissue Anatomy 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical group 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 230000017105 transposition Effects 0.000 claims 3
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 2
- 208000003782 Raynaud disease Diseases 0.000 claims 2
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 2
- 208000017442 Retinal disease Diseases 0.000 claims 2
- 206010038923 Retinopathy Diseases 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 150000001414 amino alcohols Chemical class 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 230000001771 impaired effect Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 230000000306 recurrent effect Effects 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- DYPFWPZTPLZNEM-UWVGGRQHSA-N (1s,2s)-2-[amino(methyl)amino]-2,3-dihydro-1h-inden-1-ol Chemical compound C1=CC=C2[C@H](O)[C@@H](N(N)C)CC2=C1 DYPFWPZTPLZNEM-UWVGGRQHSA-N 0.000 claims 1
- QMEQBOSUJUOXMX-UHFFFAOYSA-N 2h-oxadiazine Chemical compound N1OC=CC=N1 QMEQBOSUJUOXMX-UHFFFAOYSA-N 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 206010061666 Autonomic neuropathy Diseases 0.000 claims 1
- 208000027496 Behcet disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000033386 Buerger disease Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 claims 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000003790 Foot Ulcer Diseases 0.000 claims 1
- 206010017969 Gastrointestinal inflammatory conditions Diseases 0.000 claims 1
- 208000017189 Gastrointestinal inflammatory disease Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010065159 Polychondritis Diseases 0.000 claims 1
- 206010036105 Polyneuropathy Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 206010043540 Thromboangiitis obliterans Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 208000002399 aphthous stomatitis Diseases 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- 239000010949 copper Substances 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 235000015220 hamburgers Nutrition 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000011486 lichen planus Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 201000005518 mononeuropathy Diseases 0.000 claims 1
- 210000002200 mouth mucosa Anatomy 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 238000007034 nitrosation reaction Methods 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- SJGALSBBFTYSBA-UHFFFAOYSA-N oxaziridine Chemical compound C1NO1 SJGALSBBFTYSBA-UHFFFAOYSA-N 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 230000007824 polyneuropathy Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 230000000552 rheumatic effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 210000004761 scalp Anatomy 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 208000003265 stomatitis Diseases 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 108010028700 Amine Oxidase (Copper-Containing) Proteins 0.000 abstract 2
- 230000001684 chronic effect Effects 0.000 abstract 2
- 230000006870 function Effects 0.000 abstract 2
- 230000004968 inflammatory condition Effects 0.000 abstract 2
- 102000016893 Amine Oxidase (Copper-Containing) Human genes 0.000 abstract 1
- 102100034613 Annexin A2 Human genes 0.000 abstract 1
- 108090000668 Annexin A2 Proteins 0.000 abstract 1
- 101000694615 Homo sapiens Membrane primary amine oxidase Proteins 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 102100027159 Membrane primary amine oxidase Human genes 0.000 abstract 1
- 230000004075 alteration Effects 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 230000003915 cell function Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
- C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
- C07C243/26—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C243/28—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of a saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
- C07C243/10—Hydrazines
- C07C243/20—Hydrazines having nitrogen atoms of hydrazine groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/902,789 US6982286B2 (en) | 2001-07-12 | 2001-07-12 | Carbocyclic hydrazino inhibitors of copper-containing amine oxidases |
| US09/902,789 | 2001-07-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2004103869A true RU2004103869A (ru) | 2005-03-27 |
Family
ID=25416395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004103869/04A RU2004103869A (ru) | 2001-07-12 | 2002-07-11 | Карбоциклические гидразины в качестве ингибиторов медьсодержащх аминоксидаз |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US6982286B2 (enExample) |
| EP (1) | EP1414426B1 (enExample) |
| JP (1) | JP4377221B2 (enExample) |
| KR (1) | KR20040017289A (enExample) |
| CN (1) | CN1520290A (enExample) |
| AT (1) | ATE318589T1 (enExample) |
| CA (1) | CA2451569A1 (enExample) |
| DE (1) | DE60209504T2 (enExample) |
| ES (1) | ES2259379T3 (enExample) |
| HU (1) | HUP0401097A3 (enExample) |
| IL (1) | IL159205A0 (enExample) |
| NO (1) | NO20035139D0 (enExample) |
| RU (1) | RU2004103869A (enExample) |
| WO (1) | WO2003006003A1 (enExample) |
| ZA (1) | ZA200309112B (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6982286B2 (en) * | 2001-07-12 | 2006-01-03 | Biotie Therapies Corp. | Carbocyclic hydrazino inhibitors of copper-containing amine oxidases |
| FI20022007A0 (fi) * | 2002-11-08 | 2002-11-08 | Juvantia Pharma Ltd Oy | Oromukosaalinen valmiste ja menetelmä sen valmistamiseksi |
| US7125901B2 (en) * | 2003-01-27 | 2006-10-24 | Astellas Pharma Inc. | Thiazole derivatives |
| EP1608365B1 (en) * | 2003-03-31 | 2013-10-02 | R-Tech Ueno, Ltd. | Method for treating vascular hyperpermeable disease |
| CA2526675A1 (en) | 2003-05-26 | 2004-12-02 | Biotie Therapies Corporation | Crystalline vap-1 and uses thereof |
| FI20031927A0 (fi) * | 2003-12-31 | 2003-12-31 | Faron Pharmaceuticals Oy | Terapeuttisesti vaikuttavia aineita ja niiden käyttö |
| US8119651B2 (en) * | 2004-01-30 | 2012-02-21 | Biotie Therapies Corp. | Compositions useful especially for treatment or prevention of metabolic syndrome |
| ATE460935T1 (de) * | 2004-01-30 | 2010-04-15 | Faron Pharmaceuticals Oy | Besonders nützliche zusammensetzungen für die behandlung oder prävention des metabolischen syndroms |
| FI20040136A0 (fi) * | 2004-01-30 | 2004-01-30 | Faron Pharmaceuticals Oy | Erityisesti diabeetikoille soveltuvia koostumuksia |
| JP4140630B2 (ja) * | 2005-11-10 | 2008-08-27 | Ｔｄｋ株式会社 | 磁気ヘッドアセンブリ及び磁気ヘッドアセンブリの製造方法 |
| US8372399B2 (en) | 2006-08-31 | 2013-02-12 | Cardiac Pacemakers, Inc. | Bispecific antibodies and agents to enhance stem cell homing |
| US20080058922A1 (en) * | 2006-08-31 | 2008-03-06 | Cardiac Pacemakers, Inc. | Methods and devices employing vap-1 inhibitors |
| US8636995B2 (en) * | 2006-08-31 | 2014-01-28 | Cardiac Pacemakers, Inc. | Methods and devices to regulate stem cell homing |
| US20080207728A1 (en) * | 2006-12-15 | 2008-08-28 | Lars Wortmann | Bicyclic acyltryptophanols |
| WO2009061830A1 (en) * | 2007-11-06 | 2009-05-14 | Massachusetts Eye & Ear Infirmary | Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap-1) inhibitor |
| EP2357252A4 (en) | 2008-09-03 | 2012-05-16 | Univ Barcelona Autonoma | METHOD AND COMPOSITIONS FOR TREATING AND DIAGNOSIS OF A HEMORRHAGIC CONVERSION |
| WO2010033045A1 (en) * | 2008-09-16 | 2010-03-25 | Igor Anatolievich Pomytkin | Compositions and methods for prevention or treatment of beta amyloid deposition |
| ES2403633T3 (es) | 2008-12-04 | 2013-05-20 | Proximagen Limited | Compuestos de imidazopiridina |
| UA112154C2 (uk) | 2009-09-08 | 2016-08-10 | Біоті Терапіс Корп. | Застосування повністю людського анти-vap-1-антитіла для лікування фіброзних станів |
| GB201004311D0 (en) | 2010-03-15 | 2010-04-28 | Proximagen Ltd | New enzyme inhibitor compounds |
| FI20115234A0 (fi) | 2011-03-08 | 2011-03-08 | Biotie Therapies Corp | Uusia pyridatsinoni- ja pyridoniyhdisteitä |
| EA201490451A1 (ru) | 2011-09-14 | 2014-12-30 | Проксимаген Лимитед | Новые соединения - ингибиторы ферментов |
| GB201115853D0 (en) | 2011-09-14 | 2011-10-26 | Proximagen Ltd | New enzyme inhibitor compounds |
| GB201304527D0 (en) | 2013-03-13 | 2013-04-24 | Proximagen Ltd | New compounds |
| GB201304526D0 (en) | 2013-03-13 | 2013-04-24 | Proximagen Ltd | New compounds |
| AU2014279863A1 (en) | 2013-06-12 | 2016-01-28 | Proximagen Limited | New therapeutic uses of enzyme inhibitors |
| WO2015159112A1 (en) | 2014-04-15 | 2015-10-22 | Pécsi Tudományegyetem | Semicarbazide-sensitive amine oxidase inhibitors for use as analgesics in traumatic neuropathy and neurogenic inflammation |
| WO2015189534A1 (en) | 2014-06-12 | 2015-12-17 | Proximagen Limited | Vap-1 inhibitors for treating muscular dystrophy |
| GB201416446D0 (en) | 2014-09-17 | 2014-10-29 | Proximagen Ltd | New enzyme inhibitor compounds |
| GB201416444D0 (en) | 2014-09-17 | 2014-10-29 | Proximagen Ltd | New compounds |
| GB201521541D0 (en) * | 2015-12-07 | 2016-01-20 | Proximagen Ltd | New therapeutic uses of enzyme inhibitors |
| US20180360808A1 (en) | 2015-12-07 | 2018-12-20 | Benevolentai Cambridge Limited | Vap-1 inhibitors for treating pain |
| GB201709136D0 (en) * | 2017-06-08 | 2017-07-26 | Proximagen Ltd | New therapeutic uses of enzyme inhibitors |
| CN108033946A (zh) * | 2017-12-29 | 2018-05-15 | 佛山汉方中医医院有限公司 | 一种含金刚烷结构的ssao抑制剂、制备方法及其用途 |
| CN109988147A (zh) * | 2017-12-29 | 2019-07-09 | 佛山汉方中医医院有限公司 | 含金刚烷结构的ssao抑制剂、制备方法及其用途 |
| CN108129458A (zh) * | 2017-12-29 | 2018-06-08 | 佛山汉方中医医院有限公司 | 一种金刚烷和二甲胺吡啶结构衍生物、其制备方法及用途 |
| CN107935990A (zh) * | 2017-12-29 | 2018-04-20 | 佛山汉方中医医院有限公司 | 含金刚烷和烷氧吡啶结构化合物、其制备方法及用途 |
| CN107915719A (zh) * | 2017-12-29 | 2018-04-17 | 佛山汉方中医医院有限公司 | 一类甲基金刚烷和吡啶结构的ssao抑制剂及其用途 |
| CN108191823A (zh) * | 2017-12-29 | 2018-06-22 | 佛山汉方中医医院有限公司 | 一类烷基取代金刚烷ssao抑制剂、制备方法及其用途 |
| CN108191825A (zh) * | 2017-12-29 | 2018-06-22 | 佛山汉方中医医院有限公司 | 一种甲基金刚烷和硝基吡啶结构衍生物及其用途 |
| CN108033945A (zh) * | 2017-12-29 | 2018-05-15 | 佛山汉方中医医院有限公司 | 一种金刚烷和硝基吡啶结构化合物及用途 |
| CN107935993A (zh) * | 2017-12-29 | 2018-04-20 | 佛山汉方中医医院有限公司 | 甲基金刚烷和硝基吡啶结构衍生物、其制备方法及其用途 |
| CN107935992A (zh) * | 2017-12-29 | 2018-04-20 | 佛山汉方中医医院有限公司 | 一类含金刚烷和卤代吡啶结构化合物及用途 |
| CN108191824A (zh) * | 2017-12-29 | 2018-06-22 | 佛山汉方中医医院有限公司 | 一种甲基金刚烷和二甲胺吡啶结构衍生物、其制备方法及其用途 |
| CN108084154A (zh) * | 2017-12-29 | 2018-05-29 | 佛山汉方中医医院有限公司 | 一种金刚烷和胺基吡啶结构衍生物、其制备方法及用途 |
| CN108084155A (zh) * | 2017-12-29 | 2018-05-29 | 佛山汉方中医医院有限公司 | 甲基金刚烷和烷氧吡啶结构的ssao抑制剂及其用途 |
| CN107935989A (zh) * | 2017-12-29 | 2018-04-20 | 佛山汉方中医医院有限公司 | 金刚烷和腈基吡啶结构化合物、其制备方法及用途 |
| SE544131C2 (en) * | 2020-03-16 | 2022-01-04 | Pvac Medical Tech Ltd | Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3105849A (en) * | 1960-02-01 | 1963-10-01 | Ciba Geigy Corp | Bicyclic hydrazinium compounds |
| JP2002510300A (ja) | 1997-06-05 | 2002-04-02 | ヴィーナンティアス・リミテッド | インダン化合物及びそれらの医薬学的使用 |
| WO1998055447A1 (en) | 1997-06-05 | 1998-12-10 | Venantius Limited | 3-aminoindane derivatives, process for their preparation and pharmaceutical compositions containing them |
| AU8216301A (en) | 2000-07-05 | 2002-01-14 | Biotie Therapies Corp | Inhibitors of copper-containing amine oxidases |
| US6982286B2 (en) * | 2001-07-12 | 2006-01-03 | Biotie Therapies Corp. | Carbocyclic hydrazino inhibitors of copper-containing amine oxidases |
-
2001
- 2001-07-12 US US09/902,789 patent/US6982286B2/en not_active Expired - Fee Related
-
2002
- 2002-07-11 US US10/483,291 patent/US20040236108A1/en not_active Abandoned
- 2002-07-11 DE DE60209504T patent/DE60209504T2/de not_active Expired - Lifetime
- 2002-07-11 CN CNA028128915A patent/CN1520290A/zh active Pending
- 2002-07-11 ES ES02751224T patent/ES2259379T3/es not_active Expired - Lifetime
- 2002-07-11 IL IL15920502A patent/IL159205A0/xx unknown
- 2002-07-11 AT AT02751224T patent/ATE318589T1/de not_active IP Right Cessation
- 2002-07-11 KR KR10-2004-7000368A patent/KR20040017289A/ko not_active Withdrawn
- 2002-07-11 RU RU2004103869/04A patent/RU2004103869A/ru not_active Application Discontinuation
- 2002-07-11 EP EP02751224A patent/EP1414426B1/en not_active Expired - Lifetime
- 2002-07-11 WO PCT/FI2002/000630 patent/WO2003006003A1/en not_active Ceased
- 2002-07-11 HU HU0401097A patent/HUP0401097A3/hu unknown
- 2002-07-11 CA CA002451569A patent/CA2451569A1/en not_active Abandoned
- 2002-07-11 JP JP2003511809A patent/JP4377221B2/ja not_active Expired - Fee Related
-
2003
- 2003-11-19 NO NO20035139A patent/NO20035139D0/no not_active Application Discontinuation
- 2003-11-24 ZA ZA200309112A patent/ZA200309112B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1520290A (zh) | 2004-08-11 |
| DE60209504T2 (de) | 2006-10-12 |
| CA2451569A1 (en) | 2003-01-23 |
| US20030125360A1 (en) | 2003-07-03 |
| NO20035139D0 (no) | 2003-11-19 |
| JP4377221B2 (ja) | 2009-12-02 |
| US20040236108A1 (en) | 2004-11-25 |
| DE60209504D1 (de) | 2006-04-27 |
| ATE318589T1 (de) | 2006-03-15 |
| KR20040017289A (ko) | 2004-02-26 |
| US6982286B2 (en) | 2006-01-03 |
| HUP0401097A3 (en) | 2006-02-28 |
| ZA200309112B (en) | 2004-07-23 |
| JP2005501035A (ja) | 2005-01-13 |
| HUP0401097A2 (hu) | 2004-09-28 |
| IL159205A0 (en) | 2004-06-01 |
| EP1414426B1 (en) | 2006-03-01 |
| WO2003006003A1 (en) | 2003-01-23 |
| ES2259379T3 (es) | 2006-10-01 |
| EP1414426A1 (en) | 2004-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2004103869A (ru) | Карбоциклические гидразины в качестве ингибиторов медьсодержащх аминоксидаз | |
| RU2003103286A (ru) | Ингибиторы медьсодержащих аминооксидаз | |
| JP2005501035A5 (enExample) | ||
| DE69328910T2 (de) | Verwendung von 9-cis-Retinsäure sowie ihre Salze und Ester, zur Behandlung von Epitheltumore | |
| BE1000320A3 (fr) | Nouveaux derives de piperazinyl-1 pyrimidine, leur preparation et leur application en therapeutique et en cosmetique. | |
| JPS63146815A (ja) | イブプロフェン含有医薬組成物 | |
| RU2004122394A (ru) | Бифенилметилтиазолидиндионы и аналоги и их применение в качестве активаторов ppar-gama | |
| JP2004511516A (ja) | 膀胱の機能を調節する方法 | |
| WO2009087474A2 (en) | Agonists for antimicrobial peptide systems | |
| NO20075353L (no) | Forbindelser, isomerer og farmasoytisk akseptable salter derav, som vanilloidreseptorantagonister, og farmasoytiske preparater inneholdende slike | |
| EP2696864A1 (en) | Therapeutic compounds | |
| TW200831106A (en) | Antiinflammatory agent comprising 2-aminophenol or its derivatives as an effective ingredient(s) | |
| JP7751362B2 (ja) | 乾癬性関節炎の治療方法 | |
| KR102091464B1 (ko) | 항염증용 조성물 | |
| JP2020186259A (ja) | 光学活性ピラノクロメニルフェノール誘導体およびそれを含む薬学的組成物 | |
| TWI270544B (en) | Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them | |
| CN112174951A (zh) | 作为詹纳斯激酶1选择抑制剂的吡咯并[2，3-b]吡啶衍生物 | |
| EP4045058A1 (fr) | Utilisation de nictotinamide mononucléotide (nmn) pour la prevention et/ou le traitement de la polyarthrite rhumatoïde et compositions correspondantes | |
| ES2554332T3 (es) | Utilización de la bencidamina en el tratamiento de las enfermedades dependientes de p40 | |
| US9505756B2 (en) | Compounds useful for treating disorders related to TRPA1 | |
| JPS61204120A (ja) | 免疫調節剤 | |
| WO2025188857A8 (en) | Hdac8 degraders and uses thereof | |
| JP2001213795A (ja) | ストレス軽減剤及びそれを含有してなる皮膚外用剤 | |
| TW410217B (en) | Substituted N-arylmethylamino derivatives of cyclobutene-3,4-diones | |
| JP2005082562A (ja) | ストレス性微小循環改善剤及びそれを含有してなるストレス性疾患予防用及び／又は治療用組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20051201 |